Traws Pharma, Inc. financial data

Symbol
TRAW on Nasdaq
Industry
Pharmaceutical Preparations
Location
12 Penns Trail, Newtown, PA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Onconova Therapeutics, Inc. (to 4/1/2024), ONCONOVA THERAPEUTICS INC (to 5/26/2009)
Latest financial report
10-Q - Q2 2024 - Aug 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 226 % -49.3%
Operating Margin -61.1K % -524%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.3M shares +20.6%
Common Stock, Shares, Outstanding 25.3M shares +20.6%
Entity Public Float 24.6M USD -10.5%
Common Stock, Value, Issued 253K USD +20.5%
Weighted Average Number of Shares Outstanding, Basic 25.3M shares +20.6%
Weighted Average Number of Shares Outstanding, Diluted 25.3M shares +20.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 226K USD 0%
Research and Development Expense 9.26M USD -31.3%
General and Administrative Expense 10.1M USD +19.6%
Operating Income (Loss) -138M USD -524%
Net Income (Loss) Attributable to Parent -123M USD -2797%
Earnings Per Share, Basic -5.53 USD/shares -453%
Earnings Per Share, Diluted -5.53 USD/shares -453%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.6M USD -46.6%
Other Assets, Current 583K USD +121%
Assets, Current 18.7M USD -38.7%
Property, Plant and Equipment, Net 14K USD -17.6%
Other Assets, Noncurrent 1K USD 0%
Assets 18.7M USD -38.7%
Accounts Payable, Current 6.17M USD +21.8%
Employee-related Liabilities, Current 390K USD -47.4%
Accrued Liabilities, Current 3.51M USD +4.16%
Contract with Customer, Liability, Current 227K USD +0.44%
Liabilities, Current 9.91M USD +14.4%
Contract with Customer, Liability, Noncurrent 2.68M USD -7.82%
Liabilities 12.6M USD +8.79%
Accumulated Other Comprehensive Income (Loss), Net of Tax -33K USD -17.9%
Retained Earnings (Accumulated Deficit) -611M USD -28.9%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -106M USD -658%
Liabilities and Equity 18.7M USD -38.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.42M USD +2.62%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 25.3M shares +20.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.43M USD +2.34%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.9M USD -43.2%
Deferred Tax Assets, Valuation Allowance 174M USD +2.44%
Deferred Tax Assets, Gross 174M USD +2.44%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -123M USD -2797%
Property, Plant and Equipment, Gross 84K USD +20%
Deferred Tax Assets, Operating Loss Carryforwards 74M USD +0.87%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 4K USD +33.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.41M USD +14.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%